United Therapeutics Reports Q3

  • Posted by
  • on October 29th, 2013


United Therapeutics ($UTHR), a biotech company that specializes in pulmonary hypertension treatments, reported Q3 earnings this morning that saw net income fall 20% YoY, due in large part to SG&A expenses increasing 37%. Revenue rose 25% YoY and full year 2013 guidance was raised. From the report:

Total net revenues for the quarter ended September 30, 2013 were $302.2 million, up from $242.5 million for the quarter ended September 30, 2012. Gross margin from sales was $269.3 million for the quarter ended September 30, 2013, compared to $212.9 million for the same quarter last year. Net income for the quarter ended September 30, 2013 was $62.7 million or $1.25 per basic share, compared to $78.1 million or $1.52 per basic share for the same quarter in 2012.

“I am extremely pleased with the results of the third quarter,” remarked Martine Rothblatt, Ph.D., United Therapeutics’ Chairman and Chief Executive Officer. “Our medicines are now prescribed for more PAH patients in the United States than any other company.”


On the BeanScreen list for five months running now, UTHR continues to flirt with all-time highs. We are currently long.


The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.

blog comments powered by Disqus
Wall Street Bean Blog